Rabbit Anti-GPR119 Recombinant Antibody (EG1366) (CBMAB-EN1645-LY)

Name: Rabbit Anti-GPR119 Recombinant Antibody (EG1366)
SKU: CBMAB-EN1645-LY
Rating: 5 (1 reviews)

See all GPR119 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Rabbit

Clone

EG1366

Application

WB: 1:500~1:1000 IF: 1:100~1:500 ELISA: 1:1000

Immunogen

The antibody was produced against synthesized peptide derived from internal of human GPR119.

Specificity

Human

Antibody Isotype

IgG

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

G Protein-Coupled Receptor 119

Introduction

This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010]

Entrez Gene ID

139760

UniProt ID

Q8TDV5

Alternative Names

G Protein-Coupled Receptor 119; Glucose-Dependent Insulinotropic Receptor; G-Protein Coupled Receptor 119; G-Protein Coupled Receptor 2; GPCR2;

Function

Receptor for the endogenous fatty-acid ethanolamide oleoylethanolamide (OEA) and lysophosphatidylcholine (LPC). Functions as a glucose-dependent insulinotropic receptor. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Seems to act through a G(s) mediated pathway.

Biological Process

Adenylate cyclase-activating G protein-coupled receptor signaling pathway Source: GO_Central
Regulation of metabolic process Source: GO_Central

Cellular Location

Cell membrane

Topology

Extracellular: 1-12
Helical: 13-33
Cytoplasmic: 34-37
Helical: 38-58
Extracellular: 59-81
Helical: 82-102
Cytoplasmic: 103-125
Helical: 126-146
Extracellular: 147-164
Helical: 165-185
Cytoplasmic: 186-226
Helical: 227-247
Extracellular: 248-262
Helical: 263-283
Cytoplasmic: 284-335

Qian, Y., Wang, J., Yang, L., Liu, Y., Wang, L., Liu, W., ... & Qiao, A. (2022). Activation and signaling mechanism revealed by GPR119-Gs complex structures. Nature Communications, 13(1), 7033.

Xu, P., Huang, S., Guo, S., Yun, Y., Cheng, X., He, X., ... & Xu, H. E. (2022). Structural identification of lysophosphatidylcholines as activating ligands for orphan receptor GPR119. Nature Structural & Molecular Biology, 29(9), 863-870.

Manaithiya, A., Alam, O., Sharma, V., Naim, M. J., Mittal, S., & Khan, I. A. (2021). GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus. Bioorganic Chemistry, 113, 104998.

Zhao, J., Zhao, Y., Hu, Y., & Peng, J. (2021). Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. Cellular & Molecular Biology Letters, 26(1), 1-28.

Im, D. S. (2021). GPR119 and GPR55 as receptors for fatty acid ethanolamides, oleoylethanolamide and palmitoylethanolamide. International journal of molecular sciences, 22(3), 1034.

Li, H., Fang, Y., Guo, S., & Yang, Z. (2021). GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present). Expert Opinion on Therapeutic Patents, 31(9), 795-808.

Higuchi, S., Ahmad, T. R., Argueta, D. A., Perez, P. A., Zhao, C., Schwartz, G. J., ... & Haeusler, R. A. (2020). Bile acid composition regulates GPR119-dependent intestinal lipid sensing and food intake regulation in mice. Gut, 69(9), 1620-1628.

Yamada, Y., Terauchi, Y., Watada, H., Nakatsuka, Y., Shiosakai, K., Washio, T., & Taguchi, T. (2018). Efficacy and safety of GPR119 agonist DS-8500a in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Advances in Therapy, 35, 367-381.

Li, N. X., Brown, S., Kowalski, T., Wu, M., Yang, L., Dai, G., ... & Kelley, D. E. (2018). GPR119 agonism increases glucagon secretion during insulin-induced hypoglycemia. Diabetes, 67(7), 1401-1413.

Yang, J. W., Kim, H. S., Choi, Y. W., Kim, Y. M., & Kang, K. W. (2018). Therapeutic application of GPR119 ligands in metabolic disorders. Diabetes, Obesity and Metabolism, 20(2), 257-269.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Rabbit Anti-GPR119 Recombinant Antibody (EG1366)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry